Arrowpoint Investment Partners Singapore Pte. Ltd. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 152,712 shares of the company’s stock, valued at approximately $4,766,000. Teva Pharmaceutical Industries accounts for approximately 0.7% of Arrowpoint Investment Partners Singapore Pte. Ltd.’s holdings, making the stock its 17th biggest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of TEVA. Allworth Financial LP raised its position in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the period. Grove Bank & Trust increased its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Global Retirement Partners LLC raised its holdings in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the period. Finally, 1620 Investment Advisors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 1,823.2% during the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after purchasing an additional 1,495 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $34.38 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The business has a 50-day moving average of $32.72 and a 200-day moving average of $31.61. The stock has a market capitalization of $39.53 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 3.35 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the subject of several research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. UBS Group increased their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 421,470 shares of company stock worth $14,570,945. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.